subject area of
- Addendum to Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes: 2015 Interim Update Academic Article
- CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis Academic Article
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum Academic Article
- Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data Academic Article
- Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors Academic Article
- Lack of Health-Related Quality of Life and Patient-Centered Outcome Measures in RCTs Conducted for Diabetes Pharmacotherapy: SGLT-2 receptor inhibitors as an example Academic Article
- Management of mitochondrial diabetes in the era of novel therapies Academic Article
- Non-Severe Hypoglycemia Risk Difference Between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (Sglt2-I) as an Add-On to Metformin in Randomized Controlled Trials Academic Article
- Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials Academic Article
- Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes–2015 Interim Update Academic Article
- Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses Academic Article
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Academic Article
- Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials Academic Article
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels Academic Article
- The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice Academic Article
- Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study Academic Article
- Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review Academic Article